The short version of triple agonist fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2026-05-29. Anything still debated is marked as such rather than presented as settled.
The peptide backbone is chemically modified to resist rapid enzymatic breakdown in the body. A fatty acid side chain promotes binding to serum albumin, which slows renal clearance and supports an extended circulation time. These modifications allow less frequent administration than would be possible with an unmodified peptide. The precise contribution of glucagon receptor activation to the overall metabolic effect remains an area of active investigation, because glucagon raises glucose while also increasing energy expenditure.
Development has progressed through early- and mid-stage human studies in adults with obesity and with type 2 diabetes. Published phase 2 data reported reductions in body weight and improvements in glycemic markers over the treatment period. No regulatory agency has approved the compound for any indication, and it remains available only within controlled research settings. Whether benefits observed in trials translate into durable outcomes after treatment stops is not yet established.
Retatrutide is an investigational synthetic peptide that acts as an agonist at three distinct G protein-coupled receptors. It combines activity at the glucagon-like peptide-1 receptor, the glucose-dependent insulinotropic polypeptide receptor, and the glucagon receptor within a single molecule. This multi-receptor profile distinguishes it from earlier incretin-based compounds that engage one or two of these pathways. Researchers designed the molecule to test whether simultaneous activation produces greater metabolic effects than single or dual agonism alone.
与仅靶向单一受体的同类药物相比，瑞他鲁肽增加胰高血糖素受体成分，理论上可提高能量消耗并改变脂肪分布。临床中观察到的体重变化是否主要来自该额外机制，目前尚无定论。胃肠道反应是该类药物常见不良事件，试验中通过剂量递增和监测进行管理。停药后体重反弹、个体差异和长期耐受性仍需更多数据。
瑞他鲁肽是一种在研合成肽，同时作用于胰高血糖素样肽-1、葡萄糖依赖性促胰岛素多肽和胰高血糖素受体。该分子属于多受体激动剂类别，尚未获得任何监管机构的上市批准。当前临床开发主要针对肥胖和2型糖尿病，研究代号为LY3437943。已确立的信息包括受体靶点和部分中期试验结果；最终疗效、长期安全性和适用人群仍属开放问题。
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Not a small molecule |
| Receptor targets | GLP-1, GIP, glucagon | Triple agonist activity |
| Appearance | White to off-white powder | Lyophilized solid |
| Solubility | Soluble in water | Also in aqueous buffers |
| Storage | −20 °C or below | Protect from light and moisture |
冻干粉通常在低温环境下保存，复溶之后需要按指定条件在较短时间内使用。反复冻融和剧烈振荡可能促进聚集，低吸附容器则能减少多肽在管壁上的损失。批号、日期与处理条件的完整记录，是后续复核与问题追溯的基础。
供应环节涉及来源核实与文件审核两类工作。分析证书、批次记录以及第三方检测报告构成常见的可追溯材料。来源不清的样品很难确认身份与纯度，因此核实步骤在实际操作中具有明确意义。缺少方法细节的报告通常无法复核。
Development has progressed from single- and multiple-ascending-dose studies in healthy volunteers into larger randomized trials in adults with obesity, type 2 diabetes, and fatty liver disease. Early reports describe dose-dependent reductions in body weight and improvements in glycemic markers over treatment periods of several months. Whether the glucagon arm adds tolerability cost without added benefit is still debated. Long-term cardiovascular outcomes, effects after treatment stops, and performance in older or comorbid populations are open questions rather than settled findings. Approval status may change, so the current investigational label should be confirmed against regulatory sources.
Retatrutide is an investigational synthetic peptide developed under the code LY3437943, with a backbone derived from glucose-dependent insulinotropic polypeptide. Several non-proteinogenic residues, including alpha-aminoisobutyric acid, appear in that backbone, and a fatty diacid side chain attached through a linker extends circulation time. The molecule carries roughly thirty-nine amino acid units and a total mass near 4.7 kilodaltons. Administration is by subcutaneous injection once weekly. Published work uses both the name retatrutide and the code LY3437943.
Published information places retatrutide in clinical development rather than on the market as an approved therapy. Early-stage and mid-stage trials have examined tolerability and changes in body weight, and larger studies continue to report results over time. Open questions include the durability of effects after treatment stops, the composition of weight lost, and cardiovascular outcomes over long periods. Statements about definitive benefit should therefore be treated as provisional. Regulatory status varies by jurisdiction and changes as applications are reviewed.
Retatrutide is an investigational synthetic peptide designed to activate three distinct receptor systems within a single molecule. Its pharmacological profile combines activity at the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor. This arrangement places it within a broader class of agents often described as multi-agonists, which contrast with compounds that engage one or two targets. Research interest centers on whether simultaneous signaling produces effects that single-receptor agonists cannot achieve alone. A single molecular entity also simplifies manufacturing and delivery logistics compared with combining separate agents.
The three-receptor design places retatrutide in a distinct category relative to older incretin-based therapies. Single agonists target one receptor, and dual agonists target two. Adding a third target broadens the pharmacological footprint and introduces new trade-offs among efficacy, tolerability, and glucose control. How these trade-offs resolve in large trials is a central focus of current research.
Retatrutide is an investigational peptide studied for obesity and type 2 diabetes. It is a single synthetic molecule designed to activate three metabolic receptors simultaneously. The compound belongs to the incretin mimetic family, a group of peptides that imitate gut hormones involved in appetite and glucose control. Its research code is LY3437943, and it remains under clinical study rather than cleared for routine medical use.
Acting as a triple agonist, the molecule binds the GLP-1, GIP, and glucagon receptors. GLP-1 activity slows gastric emptying and dampens appetite, while GIP signaling contributes to insulin sensitivity and fat metabolism. Glucagon receptor engagement raises energy expenditure and encourages fat breakdown, although it can also elevate blood glucose. Combining three pathways is intended to yield larger weight reduction than single or dual agonists, and researchers continue to examine how the balance among them shapes tolerability.
Each component in the sample interacts differently with the adsorbent material and the solvents, so their rates of elution are different. These different rates lead to analytical separation of the species in the fluid that flows out of the column (the eluate). The eluate enters a specific chromatography detector such as UV detectors, which produces a graph (the chromatogram). A chromatogram is a graph of detector signal intensity versus time or the volume of the mobile phase. If the analytes are well-separated, then the chromatogram would show well-separated peaks, one per analyte. Each analyte appears in its respective time (retention time) having area proportional to its amount. Chromatography can be described as a mass transfer process involving adsorption and/or partition. As mentioned, HPLC relies on pumps to pass a pressurized liquid and a sample mixture through a column filled with the adsorbent (the active component of the column). Some analytes may strongly attach to the adsorbent rather than the eluent, while other analytes may do the opposite. That is, the analytes may have different partition coefficients, leading to the separation of the analytes. The interaction between the analyte, the solid phase, and the liquid phase, are physical or chemically reversible, usually a combination of non-covalent interactions.
Dermatological/integumental: oily skin, acne vulgaris, acne conglobata, seborrhea, stretch marks (due to rapid muscle enlargement), hypertrichosis (excessive body hair growth), androgenic alopecia (pattern hair loss; scalp baldness), fluid retention/edema. Reproductive/endocrine: libido changes, reversible infertility, hypogonadotropic hypogonadism. Male-specific: spontaneous erections, nocturnal emissions, priapism, erectile dysfunction, gynecomastia (mostly only with aromatizable and hence estrogenic AAS), oligospermia/azoospermia, testicular atrophy, intratesticular leiomyosarcoma, prostate hypertrophy, prostate cancer. Female-specific: masculinization, irreversible voice deepening, hirsutism (excessive facial/body hair growth), menstrual disturbances (e.g., anovulation, oligomenorrhea, amenorrhea, dysmenorrhea), clitoral enlargement, breast atrophy, uterine atrophy, teratogenicity (in female fetuses). Child-specific: premature epiphyseal closure and associated short stature, precocious puberty in boys, delayed puberty and contrasexual precocity in girls. Psychiatric/neurological: mood swings, irritability, aggression, violent behavior, impulsivity/recklessness, hypomania/mania, euphoria, depression, anxiety, dysphoria, suicidality, delusions, psychosis, withdrawal, dependence, neurotoxicity, cognitive impairment. Musculoskeletal: muscle hypertrophy, muscle strains, tendon ruptures, rhabdomyolysis.
== Leidenfrost temperature and surface tension effects == The Leidenfrost temperature is the property of a given set of solid–liquid pair. The temperature of the solid surface beyond which the liquid undergoes the Leidenfrost phenomenon is termed the Leidenfrost temperature. Calculation of the Leidenfrost temperature involves the calculation of the minimum film boiling temperature of a fluid. Berenson obtained a relation for the minimum film boiling temperature from minimum heat flux arguments. While the equation for the minimum film boiling temperature, which can be found in the reference above, is quite complex, the features of it can be understood from a physical perspective. One critical parameter to consider is the surface tension. The proportional relationship between the minimum film boiling temperature and surface tension is to be expected, since fluids with higher surface tension need higher quantities of heat flux for the onset of nucleate boiling. Since film boiling occurs after nucleate boiling, the minimum temperature for film boiling should have a proportional dependence on the surface tension. Henry developed a model for the Leidenfrost phenomenon which includes transient wetting and microlayer evaporation. Since the Leidenfrost phenomenon is a special case of film boiling, the Leidenfrost temperature is related to the minimum film boiling temperature via a relation which factors in the properties of the solid being used.
A music video directed by Adam Mason was released on November 1, 2018, and continued the storyline from the music video of "The One You Know". In June 2018, William DuVall said in an interview with Swedish website Rocksverige that the music video for "The One You Know" is the first chapter of what the band is hoping will be visuals for all ten songs from the album Rainier Fog, and in addition to that, will be a companion piece to the film that director Adam Mason was shooting. On August 20, 2018, the baseball team Seattle Mariners hosted a special "Alice in Chains Night" at the Safeco Field in Seattle to promote Rainier Fog, with the team offering the fans a package that included a Safeco Field terrace club ticket, access to a pre-game listening party of the album, an Alice in Chains T-shirt and a Rainier Fog CD. Jerry Cantrell also threw out the ceremonial first pitch and delivered a strike before the Seattle Mariners vs. Houston Astros game. To mark the launch of the album, on August 21, 2018, Alice in Chains performed an acoustic set at the top of Seattle's Space Needle and debuted the song "Fly". Alice in Chains were the first band to perform on the Space Needle's new "Loupe" glass floor, the world's first and only revolving glass floor 500 feet high. The concert was exclusive for an audience of SiriusXM subscribers. SiriusXM broadcast the concert on their channel Lithium on August 31, 2018.
==== 1998–1999 ==== On August 7, 1998, Andrés Pastrana Arango was sworn in as the President of Colombia. A member of the Conservative Party, Pastrana defeated Liberal Party candidate Horacio Serpa in a run-off election marked by high voter turn-out and little political unrest. The new president's program was based on a commitment to bring about a peaceful resolution of Colombia's longstanding civil conflict and to cooperate fully with the United States to combat the trafficking of illegal drugs. In July 1999, Colombian military forces attacked the town of Puerto Lleras where FARC rebels were stationed. Using U.S. supplied aircraft and equipment, and backed with U.S. logistical support, Colombian government forces strafed and bombed the town for over 72 hours. In the attack, three civilians were killed and several others were wounded as the military attacked hospitals, churches, ambulances, and residential areas. FARC rebels were forced to flee the area and many were killed or wounded. The Colombian government claimed that this was a significant victory, while human rights groups claimed this was proof that "anti-narcotics" aid was actually just military aid being used to fight a leftist insurgency.
Sources: en.wikipedia.org
F. Hoffmann-La Roche AG, commonly known as Roche (), is a Swiss multinational holding healthcare company that operates worldwide under two divisions: Pharmaceuticals and Diagnostics. Its holding company, Roche Holding AG, has shares listed on the SIX Swiss Exchange. The company headquarters are located in Basel. Roche is the fifth-largest pharmaceutical company in the world by revenue and the leading provider of cancer treatments globally. In 2023, the company’s seat in Forbes Global 2000 was 76. The company owns the American biotechnology company Genentech, which is a wholly owned independent subsidiary, and the Japanese biotechnology company Chugai Pharmaceuticals, as well as the United States–based companies Ventana and Foundation Medicine. Roche's revenues during fiscal year 2020, were 58.32 billion Swiss francs. Descendants of the founding Hoffmann and Oeri families own slightly over half of the bearer shares with voting rights (a pool of family shareholders 45%, and Maja Oeri a further 5% apart), with Swiss pharma firm Novartis owning a further third of its shares until 2021. F. Hoffmann-La Roche is a full member of the European Federation of Pharmaceutical Industries and Associations.
=== Cancer === Gp100 peptide vaccine is studied to treat melanoma. To generate a greater in vitro CTL response, the peptide, gp100:209-217(210M), is modified and binds to HLA-A2*0201. After vaccination, more circulating T cells can recognize and kill melanoma cancer cells in vitro. Rindopepimut is the epidermal growth factor receptor (EGFR)-derived peptide vaccine to treat glioblastoma multiforme (GBM). The 14-mer peptide is coupled with keyhole limpet hemocyanin (KLH), which can reduce the risk of cancer. E75, GP2, and AE37 are three different HER2/neu-derived single-peptide vaccines to treat breast cancer. HER2/neu usually has low expression in healthy tissues. E75 consisting of 9 amino acids is the immunodominant epitope of the HER2 protein. GP2 consisting of 9 amino acids is the subdominant epitope. Both E75 and GP2 stimulate the CD8+ lymphocytes but GP2 has a lower affinity than E75. AE37 stimulates CD4+ lymphocytes.
Grow Papaver Somniferum from vizyonpara.com Comprehensive profile for Papaver somniferum from MaltaWildPlants.com Opium FAQ v1.0 from Opioids.com Opium Poppy Cultivation and Heroin Processing in Southeast Asia from the School of Pacific and Asian Studies "Downward Spiral – Banning Opium in Afghanistan and Burma", Transnational Institute TNI, Debate Paper, June 2005 "Withdrawal Symptoms in the Golden Triangle – A Drugs Market in Disarray" TNI Paper by Tom Kramer et al. Chouvy P.A., 2009, "Opium. Uncovering the Politics of the Poppy", London, I.B. Tauris (Cambridge, Harvard University Press: 2010)
== Serious adverse events == Brentuximab vedotin was studied as monotherapy in 160 patients in two phase II trials. Across both trials, the most common adverse reactions (≥20%), regardless of causality, were chemotherapy-induced peripheral neuropathy (a progressive, enduring and often irreversible tingling numbness, intense pain, and hypersensitivity to cold, beginning in the hands and feet and sometimes involving the arms and legs), neutropenia (an immune system impairment), fatigue, nausea, anemia, upper respiratory tract infection, diarrhea, fever, rash, thrombocytopenia, cough and vomiting.
Sources: en.wikipedia.org
Kimon Georgiev Stoyanov (Bulgarian: Кимон Георгиев Стоянов; August 11, 1882 – September 28, 1969) was a Bulgarian general who was the Prime Minister of the Kingdom of Bulgaria from 1934 to 1935 and again from 1944 to 1946. He was considered a "master in the art of coup d'états".
Premnaspirodiene oxygenase is a cytochrome P450 protein containing heme, isolated from Hyoscyamus muticus. It uses molecular oxygen for the oxidation, which proceeds in two steps via solavetivol, and requires a partner cytochrome P450 reductase for functional expression. This uses nicotinamide adenine dinucleotide phosphate.
In Situ NMR: In situ NMR enables real-time observation of chemical and structural changes in batteries while they are operating. This is particularly important for studying transient species that only exist under working conditions, such as certain intermediate reaction products. In situ NMR has become a critical tool for understanding processes like lithium and sodium plating and dendrite formation during battery cycling. Ex Situ NMR: Ex situ NMR is used after the battery has been disassembled, allowing for high-resolution analysis of battery components. It is often employed to study a wide range of nuclei, including 1H, 2H, 6Li, 7Li, 13C, 15N, 17O, 19F, 25Mg, 29Si, 31P, 51V, 133Cs. Many of these nuclei are quadrupolar or present in low abundance, making them difficult to detect. However, ex situ NMR benefits from better sensitivity and narrower linewidths, which can be further improved by employing larger sample volumes, higher magnetic fields, or magic angle spinning (MAS).
e.g., Terpios hoshinota, leading to coral mortality from black coral disease. Nakiterpiosin-type steroids are active against the signaling pathway involving the smoothened and hedgehog proteins, a pathway which is hyperactive in a number of cancers.
Consumed in relatively large amounts (grams or ounces), macronutrients (carbohydrates, fats, proteins, water) are primarily used to generate energy or to incorporate into tissues for growth and repair. Micronutrients are needed in smaller amounts (milligrams or micrograms); they have subtle biochemical and physiological roles in cellular processes, like vascular functions or nerve conduction. Inadequate consumption of essential nutrients, or diseases that interfere with absorption, result in a deficiency state that compromises growth, survival, and reproduction. Consumer advisories for dietary nutrient intakes, such as the United States Dietary Reference Intake, are based on the amount required to prevent deficiency and provide macronutrient and micronutrient guides for both lower and upper limits of intake. In many countries, regulations require that food product labels display information about the amount of any macronutrients and micronutrients present in the food in significant quantities. Nutrients in larger quantities than the body needs may have harmful effects. Edible plants also contain thousands of compounds generally called phytochemicals which have unknown effects on disease or health including a diverse class with non-nutrient status called polyphenols which remain poorly understood as of 2024.
Sources: en.wikipedia.org
Retatrutide is an investigational synthetic peptide that activates three metabolic receptors: GLP-1, GIP, and glucagon. It is being studied for obesity and type 2 diabetes. It has not been approved for clinical use.
Earlier incretin therapies engage one or two receptors. Retatrutide adds glucagon receptor activity, which may raise energy expenditure. Whether this produces larger clinical benefits is still being tested.
It has completed phase 2 trials and moved into later-stage evaluation. No regulator has granted approval. Access outside research settings is not authorized.
尚未。它仍处于临床研究阶段，任何监管批准都取决于正在进行的试验结果和提交审评。可公开获取的信息以试验注册和会议摘要为主。